Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Masimo stock jumped Wednesday after Chief Executive Joe Kiani resigned. But, importantly, the company's other executives stayed on board.

Masimo CEO Joe Kiani Resigns Following Politan Proxy Battle; Shares Jump

Masimo said on Wednesday that Joe Kiani has decided to resign as CEO, days after shareholders voted to remove him from the company's board.

Masimo's Joe Kiani resigns as CEO after board ouster

IRVINE, Calif.--(BUSINESS WIRE)--Today the Board of Directors (the “Board”) of Masimo (Nasdaq: MASI) a leading global medical innovator, provided a series of leadership and business updates: Leadership Appointments Michelle Brennan, a current member of Masimo's Board, has been appointed interim Chief Executive Officer (“CEO”) following Chairman and CEO Joe Kiani informing the Board of his decision to resign as CEO. After being elected by shareholders at the recent Annual Meeting, Darlene Solomo.

Masimo Provides Leadership and Business Updates

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Masimo (MASI) Surges 8.7%: Is This an Indication of Further Gains?

Activist investor Politan won the two board seats it was seeking at Masimo, defeating founder Joe Kiani and another director at the shareholder vote. Politan nominees Darlene Solomon and Bill Jellison will join two others who were added to the board in a prior proxy fight.

Masimo CEO Joe Kiani ousted from board after proxy fight; Politan wins two seats

Masimo Corp shareholders elected both director candidates proposed by veteran activist investor Quentin Koffey's hedge fund Politan Capital Management, in one of the most contentious boardroom battles of the year.

Masimo shareholders elect both Politan nominees in bitter boardroom battle

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), a 9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today commented on the outcome of the Company's Annual Meeting of Stockholders (the “Annual Meeting”). Both of Politan's independent nominees – Darlene Solomon and William Jellison – were elected to the Board.1 Politan greatly appreciates the support and engagement from its fellow Masimo shareholders during this proce.

Politan Comments on Results of Masimo's 2024 Annual Meeting

Shares of Masimo have risen since the news of a court ruling against Politan. The ruling is likely to favor MASI's founder in the upcoming vote for new board members on Sept.

MASI Stock Gains as US Court Raises Concern About Politan's Ethics

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today highlighted that leading proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has updated its earlier report to reiterate its recommendation that shareholders vote FOR the election of Politan's nominees, Darlene Solomon and Bill Jellison, to the Company's Board of Directors (the “Board”) at the Annual M.

Leading Proxy Advisory Firm Glass Lewis Reiterates Recommendation That Masimo Shareholders Vote FOR Both of Politan's Independent Director Nominees

MASI's latest partnership is likely to develop a new reference platform that brings high-performing Wear OS smartwatches to market.

Masimo's Stock Up Following the New Tie-Up With Google to Boost Wear OS

Independence Realty Trust

SAN FRANCISCO--(BUSINESS WIRE)--Sourcescrub LLC, the leading deal-sourcing platform, is excited to announce the return of co-founder Prescott Nasser as CEO. With a history of driving innovation and strategic vision at the company, Nasser moves back into a full-time operating role as the company releases a string of innovative new solutions, including the industry's first complete conference planning solution. Recognizing the need for private company intelligence to drive effective dealmaking, N.

Sourcescrub Names Co-Founder as New CEO as Company Expands Its Product Differentiation

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today issued an open letter to shareholders in advance of the Company's 2024 Annual Meeting of Stockholders (the “Annual Meeting”), set for September 19. The full text of the letter is below: Dear Fellow Masimo Shareholders, Over the past several months, Politan and our independent director nominees have been fortu.

Politan Highlights Need for Further Change in Masimo's Boardroom Ahead of Thursday's Annual Meeting

MASI Collaborates with Qualcomm to develop a reference platform for Wear OS smartwatches, combining biosensing tech and Snapdragon chips to enhance performance and connectivity.

Masimo Stock Likely to Rise With Qualcomm Wear OS Partnership

Alphabet

After tangling in court with Apple over smartwatch features, medical technology company Masimo is teaming with Google. The company announced in a news release Saturday (Sept.

Google Launches Smartwatch Pact With MedTech Firm Masimo

Intuitive Surgical

Veracyte

Chicago, IL – September 16, 2024 – Today, Zacks Equity Research discusses Intuitive Surgical ISRG, Masimo Corp. MASI and Veracyte, Inc. VCYT.

Zacks Industry Outlook Intuitive Surgical, Masimo and Veracyte

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today is sharing a summary of the core issues to consider in this contest for control of the Masimo Board and urging stockholders to vote “FOR” only Masimo's Director Nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card. “For more than 35 years, the team at Masimo has poured our heart and soul into drivin.

Masimo Shares Final Thoughts Ahead of September 19 Annual Meeting Where Everything is at Stake

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today issued the following statement: “With its motion for a preliminary injunction denied, Masimo pivoted this Saturday to asking the California Federal Court to effectively invalidate Politan's current proxy card. This follows the Court's hearing on Friday on Masimo's request to delay the Annual Meeting. Masimo j.

Politan Comments on Masimo's Latest Attempt to Block a Fair Shareholder Vote

IRVINE, Calif.--(BUSINESS WIRE)--Masimo is partnering with Qualcomm Technologies to develop a comprehensive reference platform to expand the Wear OS by Google™ ecosystem.

Masimo Partners with Qualcomm to Develop Next-Generation Smartwatch Reference Platform for Original Equipment Manufacturers

IRVINE, Calif.--(BUSINESS WIRE)--Masimo announced a partnership with Google to develop a comprehensive smartwatch reference platform for OEMs building Wear OS by Google smartwatches.

Masimo Partners with Google to Develop a Reference Platform That Helps Device Manufacturers Bring High-performing Wear OS Smartwatches to Market

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today issued a statement following two rulings by the U.S. District Court for the Central District of California (“the Court”): one that finds Politan Capital Management LP (“Politan”) and Quentin Koffey are in contempt of court in connection with their September 12, 2024 violation of a court order, and another that finds Poli.

Masimo Issues Statement Following Court's Order Holding Politan and Quentin Koffey in Contempt and Finding Politan Made False Statements to Stockholders

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), issued a comment from its co-counsel – Schulte Roth & Zabel (“SRZ”) and Munger, Tolles & Olson (“Munger”) – in the California federal court case brought by Masimo seeking to block Politan from voting the proxies it collects. Michael Swartz, Co-Chair of SRZ's Litigation Group, and Bethany Kristovich, a litig.

Politan Issues Statement From Legal Advisors Schulte Roth & Zabel and Munger, Tolles & Olson Regarding Masimo Proxy Contest

ISRG, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.

3 Medical Instruments Industry Stocks to Buy on genAI and M&A Boost

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today announced that leading proxy advisory firm Egan-Jones has recommended that stockholders vote on the updated GOLD proxy card “FOR” ONLY Masimo's director nominees – Joe Kiani and Christopher Chavez – in connection with its September 19, 2024 Annual Meeting of Stockholders (the “Annual Meeting”). In summarizing its positio.

Leading Proxy Advisory Firm Egan-Jones Recommends Stockholders Vote “FOR” Masimo's Director Nominees, Joe Kiani and Christopher Chavez

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today set the record straight in response to Politan Capital Management LP (“Politan”) and Quentin Koffey's preemptive press release regarding an order from the U.S. District Court for the Central District of California that is still under seal. Masimo's lawsuit forced Politan to issue several new disclosures, including on the.

Masimo's Lawsuit Forced Politan and Quentin Koffey to Issue Corrective Disclosures on False and Misleading Statements Made to Masimo Stockholders on Issues Material to the Proxy Contest

Brightcove

PROVO, Utah--(BUSINESS WIRE)--Vivint, an NRG company, is celebrating 25 years of providing home security and peace of mind to homeowners. For the past quarter century, Vivint has led home security innovation, efficiency, and safety and is now defining what it means to have a smart home. Vivint's suite of award-winning smart home and security products includes the Outdoor Camera Pro, Spotlight Pro, and Doorbell Pro, which use Smart Deter and package protection technology to help keep property an.

News for Masimo Stock (MASI)